This may be because anti-PD-L1 treatment affects both the tumor microenvironment [e.g., T and B cells, dendritic cells (DCs), and macrophages] and the tumor itself, which frequently express PD-L1 (29, 30). This evidence concerns the gene CD274 and neoplasm.